Jefferies Sticks to Their Buy Rating for AstraZeneca (AZN)
In a report released today, Michael Leuchten from Jefferies maintained a Buy rating on AstraZeneca, with a price target of £180.00.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Leuchten is an analyst with an average return of -4.7% and a 50.44% success rate.
In addition to Jefferies, AstraZeneca also received a Buy from Citi’s Graham Parry in a report issued today. However, on March 30, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).
Based on AstraZeneca’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p15.5 billion and a net profit of p2.33 billion. In comparison, last year the company earned a revenue of p14.54 billion and had a net profit of p1.46 billion
Read More on GB:AZN:
Disclaimer & DisclosureReport an Issue
- AstraZeneca Wins Strong Shareholder Backing at 2026 AGM
- AstraZeneca Extends Fasenra’s Runway With New Long-Term Safety Study
- AstraZeneca price target raised to 16,500 GBp from 16,000 GBp at Morgan Stanley
- AstraZeneca: Oncology and CVRM Momentum, Pipeline Progress, and FX Tailwinds Underpin Raised £165 Price Target and Buy Rating
- Compugen initiated with a Buy at Lake Street
